Skip to main content
Contact Us
Subscribe
E-Edition
77°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cullinan Therapeutics Inc
(NQ:
CGEM
)
15.92
+0.14 (+0.89%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cullinan Therapeutics Inc
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 16, 2024
Via
Benzinga
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
April 16, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
April 16, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
March 14, 2024
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Cullinan Oncology: Q4 Earnings Insights
March 14, 2024
Via
Benzinga
Recap: Cullinan Oncology Q3 Earnings
November 08, 2023
Via
Benzinga
Analyst Ratings for Cullinan Oncology
August 09, 2023
Via
Benzinga
Analyst Ratings for Cullinan Oncology
July 07, 2023
Via
Benzinga
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
March 01, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
February 27, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
January 30, 2024
Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted upbeat results for its second quarter.
Via
Benzinga
Analyst Expectations for Cullinan Oncology's Future
June 15, 2023
Via
Benzinga
Expert Ratings for Cullinan Oncology
June 15, 2023
Via
Benzinga
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
December 14, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
4 Analysts Have This to Say About Cullinan Oncology
May 26, 2023
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
May 22, 2023
Via
Benzinga
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
November 03, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
October 30, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
September 06, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
October 06, 2023
Via
Benzinga
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
August 09, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
July 31, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
June 15, 2023
Via
Benzinga
Why Shares of Cullinan Oncology Jumped This Week
June 09, 2023
The company's presentation at a conference got the attention of analysts and investors.
Via
The Motley Fool
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
May 25, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
